title: Utilization of the least shrew as a rapid and selective screening model for the antiemetic potential and brain penetration of substance P and NK1 receptor antagonists.
abstract: Substance P (SP) is thought to play a cardinal role in emesis via the activation of central tachykinin NK1 receptors during the delayed phase of vomiting produced by chemotherapeutics. Although the existing supportive evidence is significant, due to lack of an appropriate animal model, the evidence is indirect. As yet, no study has confirmed that emesis produced by SP or a selective NK1 receptor agonist is sensitive to brain penetrating antagonists of either NK1, NK2, or NK3 receptors. The goals of this investigation were to demonstrate: 1) whether intraperitoneal (i.p.) administration of either SP, a brain penetrating (GR73632) or non-penetrating (e.g. SarMet-SP) NK1 receptor agonist, an NK2 receptor agonist (GR64349), or an NK3 receptor agonist (Pro7-NKB), would induce vomiting and/or scratching in the least shrew (Cryptotis parva) in a dose-dependent manner; and whether these effects are sensitive to the above selective receptor antagonists; 2) whether an exogenous emetic dose of SP (50 mg/kg, i.p.) can penetrate into the shrew brain stem and frontal cortex; 3) whether GR73632 (2.5 mg/kg, i.p.)-induced activation of NK1 receptors increases Fos-measured neuronal activity in the neurons of both brain stem emetic nuclei and the enteric nervous system of the gut; and 4) whether selective ablation of peripheral NK1 receptors can affect emesis produced by GR73632. The results clearly demonstrated that while SP produced vomiting only, GR73632 caused both emesis and scratching behavior dose-dependently in shrews, and these effects were sensitive to NK1-, but not NK2- or NK3-receptor antagonists. Neither the selective, non-penetrating NK1 receptor agonists, nor the selective NK2- or NK3-receptor agonists, caused a significant dose-dependent behavioral effect. An emetic dose of SP selectively and rapidly penetrated the brain stem but not the frontal cortex. Systemic GR73632 increased Fos expression in the enteric nerve plexi, the medial subnucleus of nucleus tractus solitarius, and the dorsal motor nucleus of the vagus, but not the area postrema. Ablation of peripheral NK1 receptors attenuated the ability of GR73632 to induce a maximal frequency of emesis and shifted its percent animals vomiting dose-response curve to the right. The NK1-ablated shrews exhibited scratching behavior after systemic GR73632-injection. These results, for the first time, affirm a cardinal role for central NK1 receptors in SP-induced vomiting, and a facilitatory role for gastrointestinal NK1 receptors. In addition, these data support the validation of the least shrew as a specific and rapid behavioral animal model to screen concomitantly both the CNS penetration and the antiemetic potential of tachykinin NK1 receptor antagonists.
authors.affiliation: Department of Basic Medical Sciences, College of Osteopathic Medicine of the Pacific, Western University of Health Sciences, Pomona, CA 91766, USA. ndarmani@westernu.edu
authors.forename: Nissar A
authors.initials: NA
authors.lastname: Darmani
authors.forename: Yaozhi
authors.initials: Y
authors.lastname: Wang
authors.forename: Joseph
authors.initials: J
authors.lastname: Abad
authors.forename: Andrew P
authors.initials: AP
authors.lastname: Ray
authors.forename: Gerald R
authors.initials: GR
authors.lastname: Thrush
authors.forename: Juan
authors.initials: J
authors.lastname: Ramirez
mesh_terms: D000818:Animals; D000932:Antiemetics / Q000627:therapeutic use*; D001921:Brain / Q000187:drug effects* / Q000378:metabolism; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical; D017615:Enteric Nervous System / Q000187:drug effects / Q000378:metabolism; D064729:Neurokinin-1 Receptor Antagonists; D016761:Oncogene Proteins v-fos / Q000378:metabolism; D010446:Peptide Fragments / Q000627:therapeutic use*; D010880:Piperidines / Q000627:therapeutic use*; D018040:Receptors, Neurokinin-1 / Q000502:physiology; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage; D054789:Ribosome Inactivating Proteins, Type 1 / Q000008:administration & dosage; D000076985:Saporins; D012788:Shrews / Q000502:physiology; D013239:Stereotyped Behavior / Q000187:drug effects; D013373:Substance P / Q000031:analogs & derivatives* / Q000378:metabolism* / Q000627:therapeutic use; D013997:Time Factors; D014018:Tissue Distribution; D014839:Vomiting / Q000139:chemically induced / Q000188:drug therapy*
chemical_list: D000932:Antiemetics; D064729:Neurokinin-1 Receptor Antagonists; D016761:Oncogene Proteins v-fos; D010446:Peptide Fragments; D010880:Piperidines; D018040:Receptors, Neurokinin-1; D011993:Recombinant Fusion Proteins; D054789:Ribosome Inactivating Proteins, Type 1; C454685:SSP-SAP fusion protein, recombinant; C068032:GR 73632; C080755:3-(2-methoxybenzylamino)-2-phenylpiperidine; D013373:Substance P; D000076985:Saporins